{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:31Z","timestamp":1790383831660,"version":"4.1.0"},"reference-count":46,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. While their efficacy has been described in osteomyelitis, bacteremia, and infective endocarditis, evidence specifically addressing cardiovascular prosthetic infections such as prosthetic valve endocarditis (PVE), cardiac implantable electronic device (CIED) infections, left ventricular assist device infections (LVAD), and prosthetic vascular graft infections (PVGI) remains limited. These conditions are particularly challenging due to biofilm formation, difficulties in achieving surgical source control, and the frequent need for prolonged or suppressive therapy. Objectives: This systematic review aimed to summarize the available literature on the use of dalbavancin and oritavancin in cardiovascular prosthetic infections, with a focus on therapeutic strategies, clinical outcomes, and safety. Methods: We performed a systematic search of PubMed, Embase, Scopus, and Cochrane Library up to 24 June 2025 in accordance with PRISMA guidelines. Eligible studies included adults treated with dalbavancin or oritavancin for cardiovascular prosthetic infections. Data on study characteristics, population demographics, causative pathogens, and microbiological profiles, antibiotic regimens, treatment duration, use of therapeutic drug monitoring (TDM), indication or non-indication for chronic suppressive therapy, adverse events, clinical outcomes, and clinical efficacy were extracted. Results: Twenty studies comprising 113 patients were identified, of whom 111 received dalbavancin and 2 oritavancin. The main infections were PVE, CIED, LVAD, and PVGI. Dalbavancin was most effective as consolidation therapy after surgery or device removal, with high cure rates. Prolonged regimens were used as bridging or in partially treated cases, sometimes supported by TDM or PET\/CT. Chronic suppressive therapy, mainly for LVAD and PVGI infections, achieved variable outcomes with relapses in about one fifth of patients. Adverse events were infrequent and generally mild. Conclusions: The included studies were highly diverse, conducted in various settings and with different objectives. Eight of the twenty included studies were single case reports on dalbavancin and oritavancin, highlighting the predominance of individual case descriptions in the available literature. Long-acting lipoglycopeptides may represent a valuable option for cardiovascular prosthetic infections. Their role appears most favorable as consolidation after adequate source control, while chronic suppressive use showed heterogeneous outcomes. This systematic review was registered on Open Science Framework. This work was supported by grants from the Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3.<\/jats:p>","DOI":"10.3390\/antibiotics14111130","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:55:15Z","timestamp":1762527315000},"page":"1130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Francesca","family":"Gavaruzzi","sequence":"first","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d-IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-0545","authenticated-orcid":false,"given":"Guido","family":"Granata","sequence":"additional","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d-IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Capone","sequence":"additional","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d-IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Chinello","sequence":"additional","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d-IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-6917","authenticated-orcid":false,"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[{"name":"Clinical and Research Department for Infectious Diseases, Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d-IRCCS, 00149 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cojutti, P.G., Tedeschi, S., Gatti, M., Zamparini, E., Meschiari, M., Siega, P.D., Mazzitelli, M., Soavi, L., Binazzi, R., and Erne, E.M. (2022). Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and\/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring. Antibiotics, 11.","DOI":"10.3390\/antibiotics11080996"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rappo, U., Dunne, M.W., Puttagunta, S., Baldassarre, J.S., Su, S., Desai-Krieger, D., and Inoue, M. (2019). Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1500-Milligram Infusion. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01024-19"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus Aureus Cells In Vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Turner, N.A., Hamasaki, T., Doernberg, S.B., Lodise, T.P., King, H.A., Ghazaryan, V., Cosgrove, S.E., Jenkins, T.C., Liu, C., and Sharma, S. (2025). Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA, 334.","DOI":"10.1001\/jama.2025.12543"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"Volume 6","author":"Rappo","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s40267-025-01153-5","article-title":"Comparing two-dose 1500 mg dalbavancin to standard of care in the outpatient treatment of invasive infections","volume":"41","author":"Friend","year":"2025","journal-title":"Drugs Ther. Perspect."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Vinuesa, D., Plata, A., Martin D\u00e1vila, P., Iftimie, S., Sequera, S., Loeches, B., Lopez-Cort\u00e9s, L.E., Fari\u00f1as, M.C., and Fern\u00e1ndez-Roldan, C. (2019). DALBACEN Cohort: Dalbavancin as Consolidation Therapy in Patients with Endocarditis and\/or Bloodstream Infection Produced by Gram-Positive Cocci. Ann. Clin. Microbiol. Antimicrob., 18.","DOI":"10.1186\/s12941-019-0329-6"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gallerani, A., Gatti, M., Bedini, A., Casolari, S., Orlando, G., Puzzolante, C., Franceschini, E., Menozzi, M., Santoro, A., and Barp, N. (2023). Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111639"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"\u0141oboda, D., Swolana, D., Joniec, M., G\u0142adysz-Wa\u0144ha, S., Gibi\u0144ski, M., Simionescu, K., Pi\u0142at, E., Go\u0142ba, K.S., Wojtyczka, R.D., and Wilczy\u0144ski, S. (Cardiol. J., 2025). ORItavancin as a Therapeutic Regimen for Cardiac Implantable Electronic Devices Infections with Multidrug-Resistant Gram-Positive Cocci (ORI-4-CIEDi) Pilot Study: Rationale and Design, Cardiol. J., Online ahead of print.","DOI":"10.5603\/cj.107098"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lupia, T., De Benedetto, I., Bosio, R., Shbaklo, N., De Rosa, F.G., and Corcione, S. (2023). Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments. Life, 13.","DOI":"10.3390\/life13040959"},{"key":"ref_15","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: A narrative review","volume":"27","author":"Fiore","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the Management of Infective Endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106749","DOI":"10.1016\/j.ijantimicag.2023.106749","article-title":"Dalbavancin as Sequential Therapy for Infective Endocarditis Due to Gram-Positive Organisms: A Review","volume":"61","author":"Fazili","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106773","DOI":"10.1016\/j.ijantimicag.2023.106773","article-title":"A Descriptive Case Series of the Relationship between Maintenance of Conservative PK\/PD Efficacy Thresholds of Dalbavancin over Time and Clinical Outcome in Long-Term Treatment of Staphylococcal Osteoarticular Infections","volume":"61","author":"Gatti","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106445","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of Therapeutic Drug Monitoring in Estimating the Duration of Dalbavancin Optimal Target Attainment in Staphylococcal Osteoarticular Infections: A Proof-of-Concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: An Analysis of the SIMPLIFI Trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Guleri, A., More, R., Sharma, R., Wong, M., and Abdelrahman, A. (2021). Use of Dalbavancin in Infective Endocarditis: A Case Series. JAC Antimicrob. Resist., 3.","DOI":"10.1093\/jacamr\/dlab099"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eimc.2024.02.010","article-title":"Dalbavancin as Consolidation Antibiotic Treatment in Infective Endocarditis, Cardiac Implantable Electronic Devices Infection and Bacteremia: Clinical Experience of 7 Years","volume":"43","year":"2025","journal-title":"Enfermedades Infecc. Microbiol. Clin. Engl. Ed."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/1120009X.2020.1823119","article-title":"Dalbavancin for Infective Endocarditis: A Single Centre Experience","volume":"33","author":"Boccia","year":"2021","journal-title":"J. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a Dalbavancin Induced Glycopeptide\/Lipoglycopeptide Non-Susceptible Staphylococcus aureus during Treatment of a Cardiac Device-Related Endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mansoor, A., Krekel, T., and Cabrera, N.L. (2023). Experience with Dalbavancin for Long-term Antimicrobial Suppression of Left Ventricular Assist Device Infections. Transpl. Infect. Dis., 25.","DOI":"10.1111\/tid.14068"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Johnson, J.A., Feeney, E.R., Kubiak, D.W., and Corey, G.R. (2015). Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus Faecium Prosthetic Valve Endocarditis. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofv156"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s15010-019-01379-2","article-title":"Dalbavancin as a Second-Line Treatment in Methicillin-Resistant Staphylococcus Aureus Prosthetic Vascular Graft Infection","volume":"48","author":"Ciccullo","year":"2020","journal-title":"Infection"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s15010-020-01526-0","article-title":"Dalbavancin as Long-Term Suppressive Therapy for Patients with Gram-Positive Bacteremia Due to an Intravascular Source\u2014A Series of Four Cases","volume":"49","author":"Hitzenbichler","year":"2021","journal-title":"Infection"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Spaziante, M., Franchi, C., Taliani, G., D\u2019Avolio, A., Pietropaolo, V., Biliotti, E., Esvan, R., and Venditti, M. (2019). Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofz427"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ruiz-Sancho, A., N\u00fa\u00f1ez-N\u00fa\u00f1ez, M., Castelo-Corral, L., Mart\u00ednez-Marcos, F.J., Lois-Mart\u00ednez, N., Abdul-Aziz, M.H., and Vinuesa-Garc\u00eda, D. (2023). Dalbavancin as Suppressive Antibiotic Therapy in Patients with Prosthetic Infections: Efficacy and Safety. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1185602"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cepeda, J.G., Perona, F.L., Sanchez, I.B., Calvo, J.C., Rico, A., and Loeches, B. (2024). Case Report: Prosthetic Aortic Valve Endocarditis Due to Staphylococcus Epidermidis with Acquired Resistance in the WalK Gene. Diagn. Microbiol. Infect. Dis., 108.","DOI":"10.1016\/j.diagmicrobio.2023.116132"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/1120009X.2022.2136426","article-title":"Dalbavancin as Chronic Antibiotic Suppression Therapy for Left Ventricular Assist Device Driveline Infection Due to Methicillin-Resistant Staphylococcus aureus: A Case Report","volume":"35","author":"Pallotto","year":"2023","journal-title":"J. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rowe, S., Green, S., Albrecht, B., and Pouch, S.M. (2023). Long-Term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofad537"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-Label Utilization of Dalbavancin and Oritavancin for Gram-Positive Infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Howard-Anderson, J., Pouch, S.M., Sexton, M.E., Mehta, A.K., Smith, A.L., Lyon, G.M., and Friedman-Moraco, R. (2019). Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofz235"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Vazquez Deida, A.A., Shihadeh, K.C., Preslaski, C.R., Young, H.L., Wyles, D.L., and Jenkins, T.C. (2020). Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofaa293"},{"key":"ref_39","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2012). The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses, ScienceOpen, Inc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological Quality and Synthesis of Case Series and Case Reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid. Based Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","article-title":"Systematic Reviews and Meta-Analyses of Randomized Trials: Principles and Pitfalls","volume":"35","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106918","DOI":"10.1016\/j.ijantimicag.2023.106918","article-title":"EN-DALBACEN 2.0 Cohort: Real-Life Study of Dalbavancin as Sequential\/Consolidation Therapy in Patients with Infective Endocarditis Due to Gram-Positive Cocci","volume":"62","author":"Loeches","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC Guidelines for the Management of Endocarditis: Developed by the Task Force on the Management of Endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","article-title":"Comparison of Dalbavancin with Standard of Care in the Management of Infective Endocarditis: Efficacy, Safety, and Cost Analysis","volume":"138","author":"Sanjurjo","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/1120009X.2024.2349442","article-title":"Chronic Antibiotic Suppressive Therapy with Dalbavancin: A Case Series","volume":"36","author":"Pallotto","year":"2024","journal-title":"J. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"106960","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:19:15Z","timestamp":1762528755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/11\/1130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["antibiotics14111130"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14111130","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}